Cardinal Health Studies Affirm Importance of Patient Reported Outcomes for Improved Quality and Reduced Costs of Care

Patient-reported outcomes (PRO) can improve quality and reduce costs of care for high-cost, complex diseases, according to new clinical studies published by Cardinal Health Specialty Solutions.

The company is unveiling a series of studies at the International Society of Pharmacoeconomic and Outcomes Research (ISPOR) annual meeting in Philadelphia, May 16-20, 2015. These studies suggest that communication with patients is important to improve the quality and reduce the costs of treatment provided to patients with complex diseases. The studies demonstrate the essential role that PRO research can play in advancing patient-centered care. Additionally, the studies illustrate the feasibility of leveraging user-friendly technology solutions to collect PRO data in real-time, at the point of care.

“As our healthcare system moves toward a value-based care model, the role of the patient is becoming increasingly important. We need to reframe the way we think about care to include not only the cost and clinical effectiveness of the treatment, but also the burden of disease and therapy on the patient’s perceived sense of well-being,” said Dr. Bruce Feinberg, vice president and chief medical officer of Cardinal Health Specialty Solutions. “Patient-reported outcomes (PRO) are key to this equation, particularly for patients being treated for high-cost, complex diseases such as cancer or rheumatoid arthritis (RA).”

One study used PRO to demonstrate that rheumatologists significantly underestimated the negative impact of RA disease burden and treatment on their patients’ sense of well-being. Understanding this disparity in perceptions can help physicians make appropriate and effective decisions on treatment that lessen the burden on patients. Additionally, this can sometimes also reduce the costs of their care.

Another study showed that PRO can be critical to identifying and managing medication access and adherence barriers for high-cost specialty drugs. Researchers contacted 239 oncology and rheumatology patients at the time of their initial prescription to provide patient reported outcomes and found that 28 percent were having problems that either restricted access or adherence to the drug. To address those challenges, interventions and support services were provided. This support resulted in an achievement of medication possession ration exceeding 95 percent, enabling almost all patients to start or continue treatment.

The last study proved the feasibility of collecting PRO at the point of care. In a study consisting of 3,185 RA patients, PRO data was captured during 90 percent of physician visits through use of the PathWare decision support tool. The participating physicians could then use the data to inform real-time treatment decision as the point of care.

“This research demonstrates that technology can be leveraged to efficiently collect patient reported outcomes at the point of care and to help physicians better understand the impact treatment has on their patients,” said Feinberg. “Equally as important, this research reinforces that when we take the time to listen to the patient, we increase our chances of being able to remove the barriers that often get in the way of even the best-laid treatment plans. In doing so, we can move even closer to value-based care by improving patient outcomes and reducing unnecessary costs.”

Source: Cardinal Health

Last updated: 5/14/15; 11:30am EST


Check Also

Natera Announces SMART Study Data for Aneuploidy and 22q Unblinded

SAN CARLOS, Calif., Sept. 2, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and …

Leave a Reply

Your email address will not be published.